ライフサイエンスコーパス: primary biliary cirrhosis

1 cholangitis (PBC, previously referred to as primary biliary cirrhosis).

2 atory response in the dnTGF-betaRII model of primary biliary cirrhosis.

3 ly phases of small bile duct injury found in primary biliary cirrhosis.

4 er murine models as well as in patients with primary biliary cirrhosis.

5 antigen of relevance for the pathogenesis of primary biliary cirrhosis.

6 lic liver disease, autoimmune hepatitis, and primary biliary cirrhosis.

7 gger that may break immunologic tolerance in primary biliary cirrhosis.

8 both of which are targets for destruction in primary biliary cirrhosis.

9 e complex (PDC)-E2, the major autoantigen of primary biliary cirrhosis.

10 PDC-E2) is the immunodominant autoantigen of primary biliary cirrhosis.

11 iral nucleotide sequences from patients with primary biliary cirrhosis.

12 evidence to suggest a viral association with primary biliary cirrhosis.

13 hepatitis, nonalcoholic steatohepatitis, and primary biliary cirrhosis.

14 ody identified in about 95% of patients with primary biliary cirrhosis.

15 study was to clarify the efficacy of UDCA in primary biliary cirrhosis.

16 study was to clarify the efficacy of UDCA in primary biliary cirrhosis.

17 oms, and/or liver histology in patients with primary biliary cirrhosis.

18 troviruses play a part in the development of primary biliary cirrhosis.

19 at UDCA improves transplant-free survival in primary biliary cirrhosis.

20 ts with features of autoimmune hepatitis and primary biliary cirrhosis.

21 granulation and reduces eosinophil counts in primary biliary cirrhosis.

22 olic liver disease, HIV/HCV co-infection and primary biliary cirrhosis.

23 dies and liver inflammation similar to human primary biliary cirrhosis.

24 enic cirrhosis (1), hemochromatosis (1), and primary biliary cirrhosis (1).

25 (1), and primary pulmonary hypertension with primary biliary cirrhosis (1).

26 IAP), on serum samples from 77 patients with primary biliary cirrhosis, 126 patients with chronic liv

27 ty was found in 27 (35%) of 77 patients with primary biliary cirrhosis, 14 (29%) of 48 patients with

28 or LAR were in seronegative hepatitis (17%), primary biliary cirrhosis (16%), and primary sclerosing

29 ding syndromes with autoimmune hepatitis and primary biliary cirrhosis (7%) or primary sclerosing cho

30 s transplanted for other indications such as primary biliary cirrhosis (8.2%; P<0.05), primary sclero

31 osis: They were most common in patients with primary biliary cirrhosis (86% [43 of 50]) and least com

32 ed a double-blind study of 165 patients with primary biliary cirrhosis (95% women) and levels of alka

33 ortant therapeutic benefits in patients with primary biliary cirrhosis, an important cholestatic live

34 ed these mutants for reactivities against 60 primary biliary cirrhosis and 103 control sera.

35 of PHB1 is markedly reduced in patients with primary biliary cirrhosis and biliary atresia or with Al

36 imary sclerosing cholangitis, in addition to primary biliary cirrhosis and biliary atresia.

37 In the vanishing bile duct syndromes (VBDS), primary biliary cirrhosis and chronic allograft rejectio

38 hing between autoimmune liver diseases, with primary biliary cirrhosis and its antimitochondrial-nega

39 mechanisms, may precipitate autoimmunity in primary biliary cirrhosis and other autoimmune diseases.

40 P antibody reactivity found in patients with primary biliary cirrhosis and other biliary disorders ma

41 nti-inflammatory effects and to benefit both primary biliary cirrhosis and primary sclerosing cholang

42 ls in intrahepatic cholestasis of pregnancy, primary biliary cirrhosis and primary sclerosing cholang

43 t also a surrogate marker of the severity of primary biliary cirrhosis and primary sclerosing cholang

44 In contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholang

45 to 12 years of treatment showed few signs of primary biliary cirrhosis and, in 3 patients, were close

46 is, alcohol-related), (2) cholestatic (e.g., primary biliary cirrhosis), and (3) cryptogenic.

47 ype 1 autoimmune hepatitis, 37 patients with primary biliary cirrhosis, and 26 patients with primary

48 pus erythematosus (SLE), Sjogren's syndrome, primary biliary cirrhosis, and active hepatitis.

49 r in patients with hepatitis C, hepatitis B, primary biliary cirrhosis, and autoimmune hepatitis.

50 d might also influence autoimmune hepatitis, primary biliary cirrhosis, and cholangiocarcinogenesis.

51 with biliary atresia, hepatitis BC, alcohol, primary biliary cirrhosis, and fulminant hepatitis.

52 c regression showed that younger recipients, primary biliary cirrhosis, and previous graft loss were

53 iver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholan

54 s for intrahepatic cholestasis of pregnancy, primary biliary cirrhosis, and primary sclerosing cholan

55 insight into the pathogenesis of gallstones, primary biliary cirrhosis, and primary sclerosing cholan

56 r assessing prognosis in biliary atresia and primary biliary cirrhosis; and important clinical trials

57 ursodeoxycholic acid) benefits patients with primary biliary cirrhosis, another cholestatic liver dis

58 tibodies (AMAs), the serological hallmark of primary biliary cirrhosis, are directed against the lipo

59 patitis, primary sclerosing cholangitis, and primary biliary cirrhosis as a group had a tendency towa

60 id (UDCA) is the only approved treatment for primary biliary cirrhosis, but its effect on disease pro

61 id (UDCA) is the only approved treatment for primary biliary cirrhosis, but its effect on disease pro

62 including primary sclerosing cholangitis and primary biliary cirrhosis, but not with single-nucleotid

63 ved biochemical test results and symptoms in primary biliary cirrhosis, but the response to methotrex

64 at lymph node homogenates from patients with primary biliary cirrhosis can induce autoantigen express

65 Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and

66 ctors play a key role in the pathogenesis of primary biliary cirrhosis, cholangiocarcinoma, liver cys

67 3 gene-spanning haplotype is associated with primary biliary cirrhosis, demonstrating the nuance of s

68 Patients with primary biliary cirrhosis develop progressive ductopenia

69 iology, pathogenesis, and natural history of primary biliary cirrhosis, discuss management of the dis

70 carcinoma, alcohol cirrhosis, hepatitis C or primary biliary cirrhosis, donor age 40 years or younger

71 genesis, clinical features, and treatment of primary biliary cirrhosis, drug-induced cholestasis, and

72 Individuals with autoimmune hepatitis and primary biliary cirrhosis entered remission during corti

73 is, new understanding of the pathogenesis of primary biliary cirrhosis, familial intrahepatic cholest

74 erosing cholangitis, cellular rejection, and primary biliary cirrhosis, four liver diseases affecting

75 Primary biliary cirrhosis frequently progresses despite

76 The typical course of primary biliary cirrhosis has changed substantially with

77 pothesis of a bacterial role in the cause of primary biliary cirrhosis has received recent attention,

78 ave found that the majority of patients with primary biliary cirrhosis have both RT-PCR and immunohis

79 otype (SASP) in livers of patients with PSC, primary biliary cirrhosis, hepatitis C, and in normals b

80 autoimmune cholangitis with similarities to primary biliary cirrhosis in humans.

81 at accurately predict the natural history of primary biliary cirrhosis in individuals.

82 rimary sclerosing cholangitis, and recurrent primary biliary cirrhosis in terms of the clinical entit

83 one third of those previously described for primary biliary cirrhosis in the same population.

84 teins was found in 37 (51%) of patients with primary biliary cirrhosis, in 28 (58%) of patients with

85 ckground increase the severity of autoimmune primary biliary cirrhosis induced by infection with Novo

86 Ursodeoxycholic acid (UDCA) is used to treat primary biliary cirrhosis, intrahepatic cholestasis, and

87 Primary biliary cirrhosis is a chronic cholestatic liver

88 Primary biliary cirrhosis is a chronic cholestatic liver

89 Primary biliary cirrhosis is a chronic inflammatory dise

90 Primary biliary cirrhosis is an immune-mediated chronic

91 pathogenesis of the autoimmune liver disease primary biliary cirrhosis is breakdown of T-cell self-to

92 Identification of primary biliary cirrhosis is important, because effectiv

93 The serological hallmark of primary biliary cirrhosis is the antimitochondrial antib

94 In some patients, primary biliary cirrhosis may remit in response to metho

95 controls (n = 10), and disease controls with primary biliary cirrhosis (n = 10).

96 (22.4%) for recurrence of original disease: primary biliary cirrhosis (n= 19), sclerosing cholangiti

97 ell as in serum samples of disease controls (primary biliary cirrhosis; n = 22).

98 , intrahepatic cholestasis of pregnancy, and primary biliary cirrhosis; new information for assessing

99 be female, white, and have the diagnoses of primary biliary cirrhosis or cryptogenic cirrhosis than

100 insulin resistance, liver disorders such as primary biliary cirrhosis or nonalcoholic steatohepatiti

101 significantly higher than from patients with primary biliary cirrhosis or nonalcoholic steatohepatiti

102 ase, and underlying liver disease other than primary biliary cirrhosis or sclerosing cholangitis were

103 Underlying liver disease other than primary biliary cirrhosis or sclerosing cholangitis, num

104 patients with alcohol-induced liver disease, primary biliary cirrhosis, or chronic hepatitis C.

105 utoimmune hepatitis (P = 0.01, HR = 4.2) and primary biliary cirrhosis (P = 0.04, HR = 2).

106 ctions of primary sclerosing cholangitis and primary biliary cirrhosis patient liver samples.

107 d in cholangiocytes from control patients or primary biliary cirrhosis patients nor in hepatocytes fr

108 Compared to healthy controls or primary biliary cirrhosis patients, PBMCs from PSC patie

109 6), (3) patients with cirrhosis secondary to primary biliary cirrhosis (PBC) (n = 6), and (4) healthy

110 s' follow-up and only included patients with primary biliary cirrhosis (PBC) according to established

111 s' follow-up and only included patients with primary biliary cirrhosis (PBC) according to established

112 noclonal antibody rituximab in patients with primary biliary cirrhosis (PBC) and an incomplete respon

113 PDC-E2) are detected in 95% of patients with primary biliary cirrhosis (PBC) and are present before t

114 gene and protein expression in the liver of primary biliary cirrhosis (PBC) and controls.

115 Comparisons were made between patients with primary biliary cirrhosis (PBC) and hepatocellular cirrh

116 xamined temporal changes in the incidence of primary biliary cirrhosis (PBC) and investigated associa

117 epatocellular carcinoma (HCC) development in primary biliary cirrhosis (PBC) and its effects on patie

118 is invoked as a strong component underlying primary biliary cirrhosis (PBC) and other autoimmune dis

119 Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing c

120 ent of cholestatic liver diseases, including primary biliary cirrhosis (PBC) and primary sclerosing c

121 e patients who underwent transplantation for primary biliary cirrhosis (PBC) and primary sclerosing c

122 Primary biliary cirrhosis (PBC) and primary sclerosing c

123 ion in 50 consecutive patients with advanced primary biliary cirrhosis (PBC) and primary sclerosing c

124 trument was administered in 96 patients with primary biliary cirrhosis (PBC) and primary sclerosing c

125 ntation among 447 transplant recipients with primary biliary cirrhosis (PBC) and primary sclerosing c

126 Primary biliary cirrhosis (PBC) and primary sclerosing c

127 rial autoantibodies (AMAs) are only found in primary biliary cirrhosis (PBC) and that a positive AMA

128 Sera from patients with primary biliary cirrhosis (PBC) are characterized by the

129 iver transplantation for classical end-stage primary biliary cirrhosis (PBC) are described, who went

130 Autoreactive T-cell responses seen in primary biliary cirrhosis (PBC) are typically of the Th1

131 recent study we showed that in patients with primary biliary cirrhosis (PBC) being positive or negati

132 on the efficacy of liver transplantation in primary biliary cirrhosis (PBC) by demonstrating that th

133 They were distinguished from primary biliary cirrhosis (PBC) by higher serum levels o

134 Patients with primary biliary cirrhosis (PBC) characteristically show

135 PSC and LTx cohort patients and primary biliary cirrhosis (PBC) control patients were ge

136 s of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year ran

137 sed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized

138 alitative studies suggest that patients with primary biliary cirrhosis (PBC) experience significant p

139 ment of cholestatic liver diseases including primary biliary cirrhosis (PBC) for which it has a posit

140 Patients with primary biliary cirrhosis (PBC) frequently experience si

141 We genotyped 2,861 cases of primary biliary cirrhosis (PBC) from the UK PBC Consorti

142 Primary biliary cirrhosis (PBC) has a complex clinical p

143 al association between cigarette smoking and primary biliary cirrhosis (PBC) has been demonstrated.

144 Our understanding of primary biliary cirrhosis (PBC) has been significantly e

145 Unlike other autoimmune liver diseases, primary biliary cirrhosis (PBC) has never been reported

146 The epidemiology of primary biliary cirrhosis (PBC) has not been studied sys

147 Controversy exists as to whether people with primary biliary cirrhosis (PBC) have an increased risk o

148 Patients with primary biliary cirrhosis (PBC) have autoantibodies that

149 the HLA locus, six genetic risk factors for primary biliary cirrhosis (PBC) have been identified in

150 Patients with primary biliary cirrhosis (PBC) have both serologic and

151 Primary biliary cirrhosis (PBC) illustrates this paradig

152 Primary biliary cirrhosis (PBC) is a chronic cholestatic

153 Primary biliary cirrhosis (PBC) is a chronic cholestatic

154 Primary biliary cirrhosis (PBC) is a chronic, cholestati

155 Primary biliary cirrhosis (PBC) is a classical autoimmun

156 Primary biliary cirrhosis (PBC) is a disease of unknown

157 Primary biliary cirrhosis (PBC) is a disease with geneti

158 Primary biliary cirrhosis (PBC) is a liver disease chara

159 Primary biliary cirrhosis (PBC) is a progressive autoimm

160 Primary biliary cirrhosis (PBC) is a progressive cholest

161 Primary biliary cirrhosis (PBC) is an autoimmune disease

162 Primary biliary cirrhosis (PBC) is an autoimmune disease

163 Primary biliary cirrhosis (PBC) is an autoimmune disease

164 Primary biliary cirrhosis (PBC) is an autoimmune disease

165 Primary biliary cirrhosis (PBC) is an autoimmune liver d

166 Primary biliary cirrhosis (PBC) is an autoimmune liver d

167 Primary biliary cirrhosis (PBC) is an autoimmune liver d

168 Primary biliary cirrhosis (PBC) is an autoimmune liver d

169 Primary biliary cirrhosis (PBC) is an organ-specific aut

170 Primary biliary cirrhosis (PBC) is an uncommon chronic c

171 Primary biliary cirrhosis (PBC) is characterized by an i

172 Primary biliary cirrhosis (PBC) is characterized by anti

173 The autoimmune liver disease primary biliary cirrhosis (PBC) is characterized by auto

174 The autoimmune liver disease primary biliary cirrhosis (PBC) is characterized by the

175 Primary biliary cirrhosis (PBC) is considered a model au

176 Primary biliary cirrhosis (PBC) is considered a model au

177 antimitochondrial antibody (AMA) response in primary biliary cirrhosis (PBC) is directed against the

178 chondrial antibody response in patients with primary biliary cirrhosis (PBC) is directed against the

179 The etiology of primary biliary cirrhosis (PBC) is far from clear.

180 Primary biliary cirrhosis (PBC) is generally a slowly pr

181 f patients with the autoimmune liver disease primary biliary cirrhosis (PBC) is increasing, although

182 The development of liver fibrosis markers in primary biliary cirrhosis (PBC) is needed to facilitate

183 Primary biliary cirrhosis (PBC) is often considered to b

184 Primary biliary cirrhosis (PBC) is sometimes diagnosed b

185 The antimitochondrial response in primary biliary cirrhosis (PBC) is the most highly direc

186 aracteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-

187 The serological hallmark of primary biliary cirrhosis (PBC) is the presence of pyruv

188 A major enigma of primary biliary cirrhosis (PBC) is the selective targeti

189 The cause of primary biliary cirrhosis (PBC) is unclear.

190 E2), a ubiquitous mitochondrial protein, and primary biliary cirrhosis (PBC) is unexplained.

191 Although the etiology and mechanism of primary biliary cirrhosis (PBC) is unknown, growing evid

192 ents with features otherwise consistent with primary biliary cirrhosis (PBC) lack antimitochondrial a

193 Patients with primary biliary cirrhosis (PBC) may be at increased risk

194 in 30.6%, autoimmune hepatitis in 8.2%, and primary biliary cirrhosis (PBC) or primary sclerosing ch

195 ablished therapy for patients with end-stage primary biliary cirrhosis (PBC) or primary sclerosing ch

196 We studied the outcome of 436 patients with primary biliary cirrhosis (PBC) or primary sclerosing ch

197 More than 95% of primary biliary cirrhosis (PBC) patients have detectable

198 BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have

199 mononuclear cells (PBMCs) from patients with primary biliary cirrhosis (PBC) produce significantly hi

200 Primary biliary cirrhosis (PBC) recurs in the allograft

201 ponsible for organ-specific tissue damage in primary biliary cirrhosis (PBC) remain an enigma, it has

202 Although the etiology of primary biliary cirrhosis (PBC) remains unknown, environ

203 olved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.

204 Autoimmune diseases such as primary biliary cirrhosis (PBC) result from failure in t

205 A significant proportion of patients with primary biliary cirrhosis (PBC) suffer from severe fatig

206 ta in both humans and murine models of human primary biliary cirrhosis (PBC) suggest that activated T

207 The incidence of primary biliary cirrhosis (PBC) varies widely between re

208 Primary biliary cirrhosis (PBC) was first described in t

209 The treatment of primary biliary cirrhosis (PBC) with conventional immuno

210 samples were collected from 91 patients with primary biliary cirrhosis (PBC), 28 immediate relatives,

211 Primary biliary cirrhosis (PBC), a chronic autoimmune li

212 noncholestatic cirrhosis, (3) patients with primary biliary cirrhosis (PBC), and (4) unselected pati

213 atic biliary epithelial cells from explanted primary biliary cirrhosis (PBC), and control liver using

214 coholic steatohepatitis (NASH), hepatitis B, primary biliary cirrhosis (PBC), and primary sclerosing

215 cer incidence of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing

216 urred in patients who subsequently developed primary biliary cirrhosis (PBC), and thus may be involve

217 ctive medical therapy for most patients with primary biliary cirrhosis (PBC), but some patients show

218 fe and effective treatment for patients with primary biliary cirrhosis (PBC), but the cost of this dr

219 he bile duct epithelium during the course of primary biliary cirrhosis (PBC), but the importance of I

220 cts are found in the livers of subjects with primary biliary cirrhosis (PBC), but the mechanisms invo

221 ome are sometimes exhibited in patients with primary biliary cirrhosis (PBC), but the postulated auto

222 The immunodominant autoantigen in primary biliary cirrhosis (PBC), E2 components of pyruva

223 Eosinophilia is a distinctive feature of primary biliary cirrhosis (PBC), especially in its early

224 destruction of biliary epithelia observed in primary biliary cirrhosis (PBC), graft-versus-host disea

225 autoimmune cholangitis that resembles human primary biliary cirrhosis (PBC), including antimitochond

226 ermore, we show that SNPs conferring risk to primary biliary cirrhosis (PBC), inflammatory bowel dise

227 In primary biliary cirrhosis (PBC), it has been postulated

228 In primary biliary cirrhosis (PBC), patients develop a mult

229 ified in the nonviral chronic liver diseases primary biliary cirrhosis (PBC), primary sclerosing chol

230 The serologic hallmark of primary biliary cirrhosis (PBC), the antimitochondrial r

231 In primary biliary cirrhosis (PBC), the major autoepitope r

232 the serum of more than 95% of patients with primary biliary cirrhosis (PBC), the major epitope being

233 To further characterize the genetic basis of primary biliary cirrhosis (PBC), we genotyped 2426 PBC p

234 ary sclerosing cholangitis (PSC), but seldom primary biliary cirrhosis (PBC).

235 body recognition and epitope modification in primary biliary cirrhosis (PBC).

236 rs with increased frequency in patients with primary biliary cirrhosis (PBC).

237 lvement in the response to biliary injury in primary biliary cirrhosis (PBC).

238 ase) were elevated in all indications except primary biliary cirrhosis (PBC).

239 n who had several clinical manifestations of primary biliary cirrhosis (PBC).

240 there is a significant genetic component to primary biliary cirrhosis (PBC).

241 oantibodies, has been extensively studied in primary biliary cirrhosis (PBC).

242 s as causative agents in the pathogenesis of primary biliary cirrhosis (PBC).

243 in primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC).

244 ne loss is a well-recognized complication of primary biliary cirrhosis (PBC).

245 MTX plus UDCA to UDCA alone on the course of primary biliary cirrhosis (PBC).

246 been recognized as a serological hallmark of primary biliary cirrhosis (PBC).

247 ptibility and environmental factors leads to primary biliary cirrhosis (PBC).

248 uman mouse mammary tumor virus (MMTV) causes primary biliary cirrhosis (PBC).

249 recognized by antimitochondrial Abs (AMA) in primary biliary cirrhosis (PBC).

250 ve been proposed as immunologic triggers for primary biliary cirrhosis (PBC).

251 be involved in generation of autoepitopes in primary biliary cirrhosis (PBC).

252 eactive T lymphocytes in the pathogenesis of primary biliary cirrhosis (PBC).

253 od and liver from controls and patients with primary biliary cirrhosis (PBC).

254 uct loss that characterizes diseases such as primary biliary cirrhosis (PBC).

255 ctive medical therapy for most patients with primary biliary cirrhosis (PBC).

256 fective treatment for patients with advanced primary biliary cirrhosis (PBC).

257 gments corresponding to the ducts damaged in primary biliary cirrhosis (PBC).

258 an important criterion for the diagnosis of primary biliary cirrhosis (PBC).

259 amounts in biliary epithelial cells (BEC) in primary biliary cirrhosis (PBC).

260 se from patients with the autoimmune disease primary biliary cirrhosis (PBC).

261 s assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC).

262 been associated with the etiopathogenesis of primary biliary cirrhosis (PBC).

263 disease (SIR 2.78); five of these cases had primary biliary cirrhosis (PBC).

264 t have opposing effects on susceptibility to primary biliary cirrhosis (PBC).

265 ctular disease that strongly resembles human primary biliary cirrhosis (PBC).

266 fractures is a complication in patients with primary biliary cirrhosis (PBC).

267 Liver biopsy is important for diagnosing primary biliary cirrhosis (PBC).

268 els described with features similar to human primary biliary cirrhosis (PBC).

269 d blood mononuclear cells from patients with primary biliary cirrhosis (PBC).

270 autoimmune biliary disease (ABD) resembling primary biliary cirrhosis (PBC).

271 ificantly influence complex diseases such as primary biliary cirrhosis (PBC).

272 toantibodies (AMAs) closely resembling human primary biliary cirrhosis (PBC).

273 69% males, 55% Caucasians) received SLK for primary biliary cirrhosis (PBC, n=76), primary sclerosin

274 as queried for adults receiving first LT for primary biliary cirrhosis (PBC; n=3052), primary scleros

275 ease from biliary causes of cirrhosis (e.g., primary biliary cirrhosis [PBC], and primary sclerosing

276 nic pruritus due to liver disease (including primary biliary cirrhosis, primary sclerosing cholangiti

277 genesis, clinical features, and treatment of primary biliary cirrhosis, primary sclerosing cholangiti

278 genesis, clinical features, and treatment of primary biliary cirrhosis, primary sclerosing cholangiti

279 of specific cholestatic syndromes including primary biliary cirrhosis, primary sclerosing cholangiti

280 stasis, and clinical trials of therapies for primary biliary cirrhosis, primary sclerosing cholangiti

281 Additionally, the diagnoses of primary biliary cirrhosis, primary sclerosing cholangiti

282 , hepatitis C with hepatocellular carcinoma, primary biliary cirrhosis, primary sclerosing cholangiti

283 roups were Laennec's cirrhosis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangiti

284 VCAM-1 was detected on BDs in CLDs (primary biliary cirrhosis, primary sclerosing cholangiti

285 ents with cholestatic liver diseases such as primary biliary cirrhosis, primary sclerosing cholangiti

286 011) queried for deceased donor first LT for primary biliary cirrhosis, primary sclerosing cholangiti

287 Primary biliary cirrhosis, primary sclerosing cholangiti

288 The precise aetiopathogenesis of primary biliary cirrhosis remains unknown, although dysr

289 disease, Crohn's disease, Addison's disease, primary biliary cirrhosis, rheumatoid arthritis, juvenil

290 Recurrent primary biliary cirrhosis (RPBC) is a histologic diagnos

291 iseases, including scleroderma, thyroiditis, primary biliary cirrhosis, Sjogren syndrome, systemic lu

292 address the role of B cells in this model of primary biliary cirrhosis, we bred B cell-deficient mice

293 also develop the phenotypic manifestation of primary biliary cirrhosis when cocultivated in serial pa

294 ontributes to breakdown of self-tolerance in primary biliary cirrhosis, whereas those of DR1101 promo

295 randomized controlled trial of patients with primary biliary cirrhosis who had an inadequate response

296 ase, compared with placebo, in patients with primary biliary cirrhosis who had inadequate responses t

297 -five patients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphata

298 Patients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphata

299 Treatment of primary biliary cirrhosis with ursodiol or colchicine ma

300 targets for autoreactive immune responses in primary biliary cirrhosis, with lipoic acid itself formi